Silence Therapeutics To Receive $2M Research Milestone Payment From Hansoh Pharma, Following The Achievement Of A Second Undisclosed Milestone Related To The First Target Under The Collaboration
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming peoples' lives by silencing diseases through precision engineered medicines, today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited ("Hansoh") following the achievement of a second undisclosed milestone related to the first target under the collaboration